Morten Frost joined Veracyte in January 2021 and serves as General Manager, Pulmonology & Breast Cancer. In this role, he has global responsibility for strategic business planning and tactical execution for the company’s lung cancer and interstitial lung disease (ILD) products, as well as the Prosigna Breast Cancer Prognostic Gene Signature Assay. Mr. Frost will lead the planned 2021 launches of the Veracyte’s noninvasive nasal swab test for early lung cancer detection, its Percepta Genomic Atlas lung cancer genomic profiling test and its global introduction of the Envisia classifier for improved ILD diagnosis on the nCounter system. Mr. Frost comes to Veracyte with significant strategic consulting, sales and marketing experience. He was most recently at Agilent Technologies, where he served as Associate Vice President, Head of Global Marketing for the company’s pathology and companion diagnostics business. In this role, he drove significant revenue growth, global product launches, biopharmaceutical partnerships and M&A strategy. Prior to that, Mr. Frost served as a management consultant at IMS Consulting Group (Now IQVIA) where he advised leading pharmaceutical companies on top-line growth and commercial strategy. Mr. Frost sits on the board of Visiopharm, a global digital pathology company with headquarters in Denmark. He holds an MSc in Economics and Business Administration from Copenhagen Business School in Denmark with complementary executive MBA courses from Stanford University.